CDNA

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

CareDx, Inc. (CDNA) is a healthcare company listed on Nasdaq, traded in USD. Over the past year it moved between $14.27 and $90.87. The 6 analysts covering it say Buy, with an average price target of $82.00.

• Healthcare
• Diagnostics & Research
• Brisbane, United States
• 761 employees
• Led by John Walter Hanna Jr.